Clinical trial
Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
NCT00348712 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00348712 |
|---|---|
| Title | Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes |
| Official title | Efficacy and Safety of Inhaled Pre-prandial Human Insulin Plus Metformin Versus Rosiglitazone Plus Metformin in Type 2 Diabetes |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | rosiglitazone, inhaled human insulin, metformin |
| Enrollment | 301 |
| Start date | Oct 30, 2006 |
| Primary completion | Mar 5, 2008 |
| Completion | Mar 5, 2008 |
| First posted | Jul 6, 2006 |
| Last update posted | Mar 1, 2017 |
| Countries | Austria, Finland, France, Germany, Ireland, Netherlands, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: